87 related articles for article (PubMed ID: 15649881)
1. Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force.
Hinkle RT; Donnelly E; Cody DB; Sheldon RJ; Isfort RJ
J Appl Physiol (1985); 2005 Feb; 98(2):655-62. PubMed ID: 15649881
[TBL] [Abstract][Full Text] [Related]
2. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function.
Hinkle RT; Donnelly E; Cody DB; Bauer MB; Isfort RJ
Endocrinology; 2003 Nov; 144(11):4939-46. PubMed ID: 12960070
[TBL] [Abstract][Full Text] [Related]
3. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions.
Hinkle RT; Donnelly E; Cody DB; Samuelsson S; Lange JS; Bauer MB; Tarnopolsky M; Sheldon RJ; Coste SC; Tobar E; Stenzel-Poore MP; Isfort RJ
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E889-98. PubMed ID: 12959937
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis.
Miotto D; Boschetto P; Bononi I; Zeni E; Cavallesco G; Fabbri LM; Mapp CE
Eur Respir J; 2004 Dec; 24(6):958-63. PubMed ID: 15572539
[TBL] [Abstract][Full Text] [Related]
5. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate.
Asnicar MA; Köster A; Heiman ML; Tinsley F; Smith DP; Galbreath E; Fox N; Ma YL; Blum WF; Hsiung HM
Endocrinology; 2002 Oct; 143(10):3994-4006. PubMed ID: 12239111
[TBL] [Abstract][Full Text] [Related]
7. Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions.
Reichart DL; Hinkle RT; Lefever FR; Dolan ET; Dietrich JA; Sibley DR; Isfort RJ
BMC Musculoskelet Disord; 2011 Jan; 12():27. PubMed ID: 21269506
[TBL] [Abstract][Full Text] [Related]
8. Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis.
Kim DH; Park IH; Cho JS; Lee YM; Choi H; Lee HM
Am J Rhinol Allergy; 2011; 25(1):e44-7. PubMed ID: 21711977
[TBL] [Abstract][Full Text] [Related]
9. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide.
Voice JK; Dorsam G; Chan RC; Grinninger C; Kong Y; Goetzl EJ
Regul Pept; 2002 Nov; 109(1-3):199-208. PubMed ID: 12409234
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of skeletal muscle atrophy via protease inhibition.
Morris CA; Morris LD; Kennedy AR; Sweeney HL
J Appl Physiol (1985); 2005 Nov; 99(5):1719-27. PubMed ID: 15976355
[TBL] [Abstract][Full Text] [Related]
11. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
12. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy.
Hinkle RT; Dolan E; Cody DB; Bauer MB; Isfort RJ
Muscle Nerve; 2005 Dec; 32(6):775-81. PubMed ID: 16116651
[TBL] [Abstract][Full Text] [Related]
14. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice.
Murphy KT; Cobani V; Ryall JG; Ibebunjo C; Lynch GS
J Appl Physiol (1985); 2011 Apr; 110(4):1065-72. PubMed ID: 21270350
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of vasoactive intestinal peptide receptors in human lower esophageal sphincter.
Jia T; Zhao N
Ann Palliat Med; 2021 Mar; 10(3):3067-3077. PubMed ID: 33849096
[TBL] [Abstract][Full Text] [Related]
16. Satellite cell regulation of muscle mass is altered at old age.
Gallegly JC; Turesky NA; Strotman BA; Gurley CM; Peterson CA; Dupont-Versteegden EE
J Appl Physiol (1985); 2004 Sep; 97(3):1082-90. PubMed ID: 15121742
[TBL] [Abstract][Full Text] [Related]
17. Atrophy and hypertrophy of skeletal muscles: structural and functional aspects.
Boonyarom O; Inui K
Acta Physiol (Oxf); 2006 Oct; 188(2):77-89. PubMed ID: 16948795
[TBL] [Abstract][Full Text] [Related]
18. Role of VIP1/PACAP receptors in postoperative ileus in rats.
De Winter BY; Robberecht P; Boeckxstaens GE; De Man JG; Moreels TG; Herman AG; Pelckmans PA
Br J Pharmacol; 1998 Jul; 124(6):1181-6. PubMed ID: 9720789
[TBL] [Abstract][Full Text] [Related]
19. Clenbuterol attenuates muscle atrophy and dysfunction in hindlimb-suspended rats.
Dodd SL; Koesterer TJ
Aviat Space Environ Med; 2002 Jul; 73(7):635-9. PubMed ID: 12137098
[TBL] [Abstract][Full Text] [Related]
20. VPAC2 receptor activation mediates VIP enhancement of population spikes in the CA1 area of the hippocampus.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Ann N Y Acad Sci; 2006 Jul; 1070():210-4. PubMed ID: 16888168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
